Quantcast

Latest Rosetta Genomics Stories

2011-07-20 08:00:00

LA JOLLA, Calif., July 20, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. This selection represents another significant milestone for Regulus in its microRNA alliance with GSK, which is focused on the discovery and...

2011-07-14 08:00:00

LA JOLLA, Calif., July 14, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has added Gregory Hannon, Ph.D. to its Scientific Advisory Board (SAB). The addition of Dr. Hannon, a researcher whose work has involved the molecular identification and characterization of the microRNA pathway, increases SAB membership to six pioneers in this area of scientific...

2011-07-06 07:01:00

PHILADELPHIA and REHOVOT, Israel, July 6, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the effectiveness of a one-for-four reverse stock split of its share capital. The reverse stock split, which was previously approved by the Company's Board of Directors, was approved by its shareholders at the 2011 Annual General Meeting of Shareholders of the Company held earlier today. The...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related